MIF-Dependent Control of Tumor Immunity

Jordan T. Noe1,2 and Robert A. Mitchell1,2,3,4*

1 Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, United States, 2 J.G. Brown Cancer Center, University of Louisville, Louisville, KY, United States, 3 Department of Surgery, Division of Immunotherapy, University of Louisville, Louisville, KY, United States, 4 Department of Microbiology and Immunology, University of Louisville, Louisville, KY, United States

Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage migration inhibitory factor (MIF) has since been found to be expressed by nearly every immune cell type examined and overexpressed in most solid and hematogenous malignant cancers. It is localized to both extracellular and intracellular compartments and physically interacts with more than a dozen different cell surface and intracellular proteins. Although classically associated with and characterized as a mediator of pro-inflammatory innate immune responses, more recent studies demonstrate that, in malignant disease settings, MIF contributes to anti-inflammatory, immune evasive, and immune tolerant phenotypes in both innate and adaptive immune cell types. This review will summarize the studies describing MIF in tumor-specific innate and adaptive immune responses and attempt to reconcile these various pleiotropic functions in normal physiology.

Keywords: migration inhibitory factor, cytokines, tumor immunity, immunotherapy, macrophages, lymphocytes, dendritic cells, immune evasion

INTRODUCTION

Tumor immune responses are shaped and characterized by a number of factors (1) including mutational burden, inflammatory response, differential expression of cytokines and chemokines, and the presence and/or activation of both tumoral and stromal immune suppressive checkpoint ligands and receptors.

Originally identified over 50 years ago as a secreted lymphocyte product associated with macrophage-dependent delayed-type hypersensitivity (2, 3), MIF has become one of the most enigmatic regulators of innate and adaptive immune responses. Following its initial cDNA cloning in the late 1980s (4), further characterization studies identified MIF’s expression in myeloid lineage cells (5) and discovered its functional importance in driving innate immune responses [reviewed in (6)]. Although MIF was first discovered in the early 1960s, the first description of a functional role for MIF in facilitating T cell responses came more than 30 years later (7).

Since these early findings, MIF has been shown to be involved—either as an autocrine or paracrine-acting cytokine—in functional phenotypes associated with innate myeloid, neutrophil, gamma delta (γδ) T cell and adaptive Th1, Th2, Th17, NKT, and B cells. Because each of these cell types influences the initiation, growth, progression, and/or metastatic dissemination of tumors, we will attempt to summarize how MIF shapes tumor-associated immune responses focusing on individual cell effectors and their relative contributions to pro/anti-tumor immunity.
MIF'S MECHANISMS OF ACTION

MIF elicits bio-actions via both extracellular and intracellular mechanisms (Figure 1). Prototypical outside-in signaling occurs by extracellular MIF binding to receptor/co-receptor complexes on the cell surface while intracellular MIF can act in a receptor-independent manner by physically interacting with various intracellular proteins and enzymes thereby modifying their specific effector functions [reviewed in (8)]. It is likely that MIF’s site of action—either extracellular or intracellular—as well as which receptor/co-receptor or intracellular protein/enzyme MIF interacts with, is ultimately responsible for specific phenotypes elicited by MIF.

MIF expression and secretion is elevated in most solid and hematogenous cancers and high MIF expression is a negative prognostic indicator in several cancer types (9). The extent of MIF expression is dependent on the tumor tissue type, stage, and grade among other factors (10). For example, intratumoral MIF is increased—versus normal tissue—three- and five-fold in endometrial carcinoma and non-small cell lung carcinoma (11, 12), respectively, ten times in hepatocellular carcinoma (13) and sixty times in colorectal cancer (14). In hepatocellular carcinoma, a positive correlation was also identified between intratumoral MIF and plasma MIF, suggesting that high tumor-associated MIF expression may drive higher circulating levels of soluble MIF (13).

The current understanding by which MIF gets into or out of a cell is rather limited and the findings so far suggest atypical features. Intracellular MIF can be stored in the cytosol or secreted into the extracellular space. As MIF does not have an N-terminal signal peptide required for the classical ER/Golgi-dependent secretory pathway, MIF is instead secreted in a non-classical protein export route through ATP binding cassette transporter subfamily 1 (ABCA1) (15). Additionally, intracellular pools of MIF have also been suggested to be generated, at least in part, through cellular uptake via clathrin-mediated endocytosis with subsequent localization in lysosomal and cytosolic compartments (16, 17). While the exact pathways involved in how endocytosed MIF crosses endosomal or other vesicular membranes remains enigmatic (18), cellular uptake studies indicate that exogenous MIF is taken up by both immune and non-immune cells with subsequent interactions with cytosolic binding partners (16).

In addition to cancer cells, MIF is upregulated in myeloid and lymphocyte lineage cell types in response to various activating ligands as well as DAMPs (19), PAMPs (20, 21), and environmental metabolic changes (8, 22). Once secreted, MIF can

---

**FIGURE 1** | Mechanisms of MIF signal transduction. Paracrine/autocrine extracellular MIF or endogenously produced cytosolic MIF functionally interacts with cytosolic Jab1/CSN5 resulting in differential cullin-ring ligase (CRL) substrate proteasomal degradation and/or c-Jun phosphorylation/AP-1 activation. Extracellular MIF independently interacts with CD74 in hetero-complex with CD44, CXCR2, CXCR4, and/or CXCR7 to initiate downstream MAPK and/or PI3K pathway effectors.
signal in either a paracrine or autocrine fashion by binding to transmembrane receptors leading to intracellular transduction cascades (22, 23). The Bucala group originally identified CD74, the invariant chain of the major histocompatibility complex II (MHCII), to be a primary cognate receptor for MIF (24). Extracellular binding of MIF to cell surface CD74 initiates signal transduction through the ERK MAP kinase cascade resulting in cellular proliferation and prostaglandin E2 (PGE2) production (24). Additional studies suggest that following CD74 receptor binding, MIF undergoes endocytosis to sustain this signal transduction cascade—while still in the endosome—through CD74-dependent recruitment of β-arrestin1 and subsequent ERK activation (17). Because CD74 does not possess a cytoplasmic tail capable of instigating downstream signaling, MIF-bound CD74 forms a hetero-complex with CD44 which then allows for canonical ERK Map Kinase pathway activation (25).

In addition to signaling through CD74/CD44 complexes, MIF has also been shown to be a non-cognate ligand for the chemokine receptors CXCR2, CXCR4, and CXCR7 and acts as a chemokine-like molecule resulting in monocyte activation of Gzii- and integrin-dependent adhesion and recruitment (26–28). Given that these receptors are variably expressed on numerous immune cell types implicated in different aspects of tumor immune responses, the effector function(s) and biological activities elicited by extracellular MIF are likely highly dependent on signals stemming from the microenvironment and immune landscape within the tumor stroma that control relative expression levels of each.

In addition to its extracellular receptor-dependent functions, cytosolic MIF binds to several different intracellular proteins to modulate their biological activities. The best characterized of these intracellular effectors is the COP9-signalsome subunit 5 (CSN5), which is an important determinant of cullin-dependent protein turnover (29, 30). CSN5 has also been shown to dissociate from the CSN complex where it can facilitate transactivation of c-Jun transcription and, in this context, is also referred to as Jun-activation domain-binding protein (Jab1) (31). Bernhagen’s group first identified that MIF negatively regulates the activity of cytosolic Jab1 on both steady-state and stimulus-induced AP-1-dependent transcription (18, 32). Given that AP-1 is associated with activation of pro-inflammatory responses in numerous immune cell types (33, 34), an anti-inflammatory/immunosuppressive role for MIF might be expected when intracellular MIF concentrations are at sufficient levels to functionally inhibit Jab1/CSN5. In contrast to intracellular MIF, extracellular MIF/CD74 interaction is shown to functionally activate c-Jun phosphorylation and increase AP-1-dependent transcription (35–37) so it is conceivable, if not likely, that the relative balance between extracellular and intracellular MIF levels in a tumor microenvironment or the circulation at any given time dictates the ensuing MIF-associated phenotype.

In addition to its AP-1 regulatory activities through Jab1 binding, MIF also modulates Jab1/CSN5-dependent ubiquitylation/proteasomal degradation of a variety of proteins. These include p27Kip1 (18), Cdc25A (38), E2F family members (38), and, more recently, HIF-1α (39, 40). In hypoxic tissues, such as the tumor microenvironment, there is a reciprocally synergistic relationship between MIF and HIF-1α: hypoxia-driven HIF-1α stabilization and subsequent transcriptional regulation promotes an enhanced expression of MIF (41). This ensuing increase in MIF promotes interaction with CSN5 to prevent the degradation of HIF-1α—either by sterically preventing HIF1α prolyl-564 hydroxylation by direct binding or by binding to VHL and preventing the recognition/ubiquitination of hydroxylated HIF1α that is targeted for proteasomal degradation (42)—which in turn amplifies the transcriptional response of HIF-1α (39). Given the important role of HIF-1α in regulating the phenotypes and relative differentiation/maturation of multiple different immune cell types (43), intracellular MIF-mediated HIF-1α stability may be a centrally important mechanism of action responsible for several of the MIF-associated pro/anti-tumor immune phenotypes described below.

**TUMOR-ASSOCIATED MACROPHAGES**

Tumor-associated macrophages (TAMs) are innate immune cells of the myeloid lineage that reside within the tumor following infiltration as either immature monocyte/macrophages (44, 45) or monocytic myeloid-derived suppressor cells (MDSCs) (46). TAMs are increasingly being recognized as central determinants in the shaping of the angiogenic, matricellular, and immune composition of tumor microenvironments [reviewed in (35–37)]—so much so that there are now numerous active clinical trials seeking to modify or disrupt TAM-dependent pro-tumorigenic phenotypes (47).

TAMs have a “yin-yang” relationship in tumor initiation and progression depending on both the tumor stage and the phenotype of the TAM. Intratumoral TAM polarization is dictated by the composition of tumor-derived vs. immune cell-derived cytokines (48, 49), growth factors (50, 51), oxygenation (52, 53), and metabolic substrate composition (54, 55) among many other factors. Combined, these factors govern whether TAMs are differentially polarized toward a more pro-tumor phenotype or anti-tumor phenotype although, in reality, there is a broad spectrum of TAM activation/polarization profiles across different tumors and even within the same lesions (56). Despite this phenotypic heterogeneity, the classical M2 and M1 TAM phenotype nomenclature can be useful in denoting anti-inflammatory, pro-tumor vs. inflammatory, anti-tumor behaviors, respectively (57).

“M1”-TAMs have an inflammatory/immunostimulatory phenotype as they can activate adaptive immune responses and produce inflammatory biomolecules (e.g. reactive oxygen and nitrogen species—ROS and NOS), lipids (e.g. prostaglandins, leukotrienes), and cytokines (e.g. IL-1β, TNF-α, IL-6). During tumor initiation, early-stage metastasis, and ensuing cancer-related inflammation, M1-TAMs accumulate and promote the elicitation of an inflammatory, anti-tumor response via phagocytosis of tumor cells (58–60), tumor-antigen...
presentation (61, 62), and production of inflammatory biomolecules and cytokines (63, 64). Conversely, anti-inflammatory/immunosuppressive "M2" TAMs promote wound healing and resolution of chronic inflammatory responses that would otherwise drive tumor initiation (65), but in the context of established tumors, M2-TAMs promote evasion of anti-tumor immunity (66–72), de novo neoangiogenesis (73, 74), and extracellular matrix remodeling (75).

Classically, MIF is best known as a centrally important driver of local and systemic inflammation. Although MIF was initially identified as a product of activated T cells that acts in a paracrine manner to modulate the relative motility of myeloid lineage cells (3), subsequent studies found that macrophages are also an abundant and important source of MIF (5). MIF expression/activity in macrophages has been implicated in the pathogenesis of numerous inflammatory conditions including bacterial sepsis (20, 76–78), rheumatoid arthritis (79, 80), acute respiratory distress syndrome (ARDS) (81, 82), and atherosclerosis (79, 83). Consistent with these findings, MIF is instrumental in driving maximal inflammation associated with carcigenesis and early-stage hyperplasia/carcinoma (84). This is especially true for inflammatory colitis, which is an exceptionally common pre-condition/pre-requisite for colorectal adenoma and adenocarcinoma progression (85). Macrophage MIF is transcriptionally induced and secreted by pro-inflammatory cytokines, TNF-α, and IFN-γ (5), and loss or inhibition of MIF in differentiated macrophages exposed to E. coli lipopolysaccharide (LPS) or S. aureus enterotoxin results in substantially reduced levels of TNF-α, IL-6, iNOS, and Cox-2 (86, 87).

The first studies to suggest that MIF may also be involved in governing the activation states of more "M2"-like macrophages came from studies that identified non-small cell lung carcinoma (NSCLC) cell-derived MIF is responsible for increased angiogenic activity of co-cultured human monocytes (88). These studies concluded that paracrine acting, tumor-derived MIF is responsible for initiating monocyte/macrophage-dependent angiogenesis and, likely, subsequent tumor progression. Macrophage-derived MIF was later reported to both sufficient and necessary for driving the angiogenic contribution of bone-marrow-derived macrophages to teratoma formation in mice suggesting a dominant functional role for monocyte/macrophage-derived MIF in M2 macrophage functional polarization (89). These findings were later confirmed using mouse models of both primary and metastatic melanoma in MIF+/+ and MIF−/− mice (90). In these studies, macrophage-derived MIF was necessary for maximal angiogenic growth factor expression in M2 alternatively activated macrophages and required for the T cell immunosuppressive capacity of melanoma-polarized TAMs. Importantly, both MIF-deficient and MIF small molecule inhibitor 4-IPP-treated TAMs were found to spontaneously revert to an M1-like polarization profile (90, 91). Combined, these findings indicate that loss or inhibition of MIF in solid tumor settings very efficiently re-polarizes intratumoral TAMs from an immunosuppressive/angiogenic pro-tumor phenotype to an immunostimulatory/non-angiogenic anti-tumor phenotype (90).

Although a unifying mechanism that explains how MIF contributes to these seemingly divergent M1 (inflammatory/immune-stimulatory) and M2 (anti-inflammatory/immune-suppressive) macrophage phenotypes is still lacking but one potential explanation could be that MIF provides an amplification or general activation phenotype in macrophages that acts to simply support generalized M1 or M2 gene expression patterns. This could be through promoting metabolic, transcriptional, and/or epigenetic pathways that broadly contribute to the general activation properties of infiltrating macrophages. It is also possible that differential expression of MIF receptors governed by microenvironmental polarization cues could explain the M1 vs. M2 effects of MIF. While further investigations will help to elucidate these mechanistic details, it is becoming increasingly evident that MIF plays an important regulatory role in governing TAM-dependent tumor initiation, progression, and metastatic disease phenotypes.

**MYELOID-DERIVED SUPPRESSOR CELLS**

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of highly suppressive immature myeloid cells found in both the circulation and intratumoral space. Despite the name, there are at least two different sources of MDSCs in human cancer patients—the first arises from polymorphonuclear (PMN) bone marrow precursors (PMN-MDSCs) and the second from monocytic bone marrow precursors (M-MDSCs) (please see comprehensive MDSC reviews (92–94)).

MIF was first reported to promote MDSC functional accumulation as a consequence of breast cancer cell secretion and paracrine activity towards M-MDSC differentiation in mouse models of breast cancer (95). shRNA knockdown of MIF in murine breast cancer cell lines diminished primary tumor outgrowth and dramatically reduced numbers of lung micro-metastases in immunocompetent Balb/c mice but not in immune-deficient SCID mice. This anti-tumor phenotype associated with MIF-deficient 4T1 breast cancer tumors was attributed to the elicitation of significantly fewer intratumoral M-MDSCs in both the in vivo breast cancer models and in an in vitro model of M-MDSC differentiation. Interestingly, reconstitution of shRNA-resistant wildtype MIF largely reverts the slow growth and metastases-resistant phenotype of 4T1 MIF shRNA knockdown cells and restores M-MDSC numbers while an enzymatically inactive MIF mutant construct (MIF-P2G) does not (95).

An additional example of paracrine-acting MIF driving MDSC phenotypes came from the Lathia group which identified that glioblastoma (GBM) cancer stem cell (CSC)-secreted MIF increases MDSC immune suppressive activity in an arginase 1-dependent manner (96). Interestingly, only GBM CSCs—but not non-stem GBM cells—were responsible for this MIF-dependent MDSC phenotype even though MIF was expressed (albeit variably and higher in CSCs) in both cell types. In a follow-up study, infiltrating M-MDSCs were shown to highly express the cognate MIF receptor, CD74, while G-
MDSCs primarily express the non-cognate CXCR2 receptor and exhibit only minimal tumor infiltration (97). Importantly, Ibudilast—which inhibits MIF enzymatic activity and MIF: CD74 interactions (98)—reduces MDSC function and increases CD8+ T cell infiltration in mouse models of GBM (97).

These data are consistent with our lab’s finding that MIF-stromal deficiency and the small molecule MIF enzymatic inhibitor, 4-IPP (99), reduce melanoma primary and metastatic tumor growth in a manner that coincides with reduced M-MDSC and PMN-MDSC (aka, G-MDSCs)-dependent immune suppression (90). An important difference, however, is that stromal MIF—as opposed to tumor cell or CSC-derived MIF—is responsible for maximally driving M-MDSC and G-MDSC immune-suppressive activities despite the very high MIF expression/secretion still present in the melanoma cell lines used for the tumor implantation studies (90). This requirement for stromal MIF in promoting tumor burden phenotypes is consistent with other reports showing that loss of stromal MIF reduces MDSC accumulation and/or tumor growth in de novo oral carcinogenesis (100) and human melanoma (101). It is presently unclear why different syngeneic tumor cell lines have differential tumor cell MIF requirements but it seems plausible that endogenous, autocrine acting myeloid cell MIF and paracrine acting tumor cell MIF are both capable of promoting MDSC differentiation and immune suppression (101). However, the fact that MIF P2G mutants and 4-IPP-mediated MIF inhibition (4-IPP specifically interacts with and disrupts the Pro-2 in MIF (99)) abolishes MIF-dependent effects on MDSCs (90, 95) suggests that the cognate MIF receptor CD74—which can still interact with and signal by MIF-P2G mutants (102) and 4-IPP-inhibited MIF (103)—is not centrally involved.

More recent studies revealed that MDSC-derived autocrine MIF is necessary for maximal immunosuppression of primary M-MDSCs isolated from the peripheral blood of stage III-IV metastatic melanoma patients (101). 4-IPP phenocopies its mouse MDSC inhibitory effects in human CD14+/HLA-DRlow monocytic MDSCs and suppresses antigen-independent proliferation of autologous T cells and IFN-γ production. Perhaps more importantly, exposure of patient MDSCs to 4-IPP for longer periods of time results in reductions in the expression of MDSC markers CD14 and PD-L1 and a simultaneous increase in the expression of dendritic cell (DC) markers CD80, CD83, CD86, and CD40 (101). Notably, this apparent induction of MDSC→DC phenotypic differentiation by 4-IPP results in functional DC maturation/activation and subsequent antigen-dependent T cell activation—an effect that is phenocopied by MIF7−/− MDSCs (101).

Other studies identifying a contributory role for MIF in MDSC-dependent tumor progression include a finding that an IG-CDR-based peptide that disrupts MIF-CD74 signaling is sufficient to reduce M-MDSC accumulation in metastatic melanoma lesions (104). This supports the GBM study suggesting a MIF-CD74 specific function in driving M-MDSC intratumoral accumulation and, likely, immune suppression (97). Also consistent with a paracrine function for tumor-derived MIF, M-MDSC differentiation is induced by human pediatric rhabdomyosarcoma and multiple myeloma cell lines in a MIF-dependent manner (105, 106) and that MIF induces the recruitment and accumulation of M-MDSCs into bladder cancer lesions (107). Interestingly, this study—in contrast to GBM and metastatic melanoma studies—found that the non-cognate MIF receptor CXCR2 was responsible for this activity.

Collectively, these studies clearly point to a centrally important role for MIF in driving tumor-associated MDSC phenotypes. What is far less clear is the mechanism and respective sources of MIF that are used to maintain these MDSC activities which range from homing, motility, expansion, differentiation, and immune-suppressive function. More studies are needed to delineate the respective mechanism(s) for MIF in driving these MDSC phenotypes, but we can tentatively conclude that soluble, extracellular MIF likely signals through at least CD74—perhaps in concert with chemokine co-receptors to control some MDSC phenotypes associated with homing, motility and expansion (108–110). It is also conceivable—given that the CD74-binding competent MIF-P2G mutant (102) and 4-IPP-inhibited MIF (103)—that intracellular MDSC MIF may be independently involved in dictating MDSC differentiation and immune-suppressive gene expression patterns.

**DENDRITIC CELLS**

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that can either promote anti-tumor immunity through presentation of tumor-associated antigens (TAAs) or drive tolerance of anti-tumor immune responses by promoting T cell anergy (111). Several studies investigating potential roles for MIF in DC-dependent anti-tumor immunity suggest that MIF functionally impairs the ability of DCs to present TAAs to T cells leading to a dampening of anti-tumor responses.

One such study found that loss of tumor-derived MIF significantly enhances DC tumor accumulation, effector functions and, anti-tumor immunity (112). Knockdown of MIF in 4T1 cells increased intratumoral infiltration of CD11c+/CD8+/CD103+ DCs and increased the expression of DC co-stimulatory CD40 and CD86 receptors. This phenotype corresponded to increased CD4+ and CD8+ T cell tumor-infiltration and resultant increases in anti-tumor T lymphocyte IFN-γ production. The mechanism by which loss of tumor-derived MIF increased DC tumor accumulation was attributed to enhanced tumor cell cytolysis and ensuing tumor-associated antigen release (112).

Similar DC-inhibiting phenotypes associated with MIF have also been shown to regulate DC intratumoral infiltration, DC maturation, and DC migration all of which conspire to reduce T cell effector functions (112–114). In one such report, the effects of MIF on directly suppressing Th1 T cell activation was ruled out using neutralizing anti-MIF antibodies which were found to be unable to attenuate tumor supernatant-induced suppression of T cell proliferation in vitro (115).

Given the similarities, it is tempting to speculate that the requirement for MIF in maintaining M-MDSC differentiation/restraining spontaneous DC differentiation, described above (101),
may also be participating in these observed increases in intratumoral DC functions upon loss of MIF. If true, we would anticipate that the observed increases in DC function would be accompanied by a reduction in intratumoral M-MDSCs (90, 101, 116).

DCs present antigens to CD4+ T cells via MHC-II or cross-present antigens to CD8+ T cells via MHC-I. Consistent with a MIF-dependent inhibition of antigen presentation, co-culture of purified CD8+ T cells with MIF-treated, tumor antigen-pulsed DCs reduced the ability of CD8+ to lyse tumor cells (104). Given that DCs cross-present antigens to CD8+ T cells via MHC-I (117), this finding indicates that MIF promotes immunosuppression, in part, by dampening DC cross-presentation of tumor antigens. Additionally, studies that looked at DC MHC-II expression found that MIF promotes downregulation of MHC-II (104, 112), which further suggests that MIF may also impair tumor antigen presentation of DCs to CD4+ T cells. Combined, these findings suggest that MIF promotes tumor-associated immune evasion by inhibiting DC infiltration, maturation, and antigen presentation; all of which are inherently required for the development of anti-tumor CD4+ and CD8+ T cell effector functions.

### TUMOR-ASSOCIATED NEUTROPHILS (TANS)

Similar to TAMs, tumor-associated neutrophils (TANS) exhibit plasticity in the tumor microenvironment and can exist as various phenotypic subtypes depending on the composition and makeup of the tumor microenvironment (118). While the functional role for MIF in TAN biology has not been fully characterized, studies indicate that MIF influences TAN tumoral infiltration and TAN functional phenotypes.

In head and neck cancer (HNC) specimens, high levels of MIF correlate with CD66b (marker of granulocytes/neutrophils), lymph node metastasis, and reduced overall survival (119). Mechanistically, tumor-derived MIF promotes neutrophil chemotaxis through outside-in CXCR2 signaling and increases the production of neutrophil-derived CCL4 and MMP9 (119). MIF-induced CCL4 and MMP9 production in TANS may have tumor autonomous effects by promoting lymphangiogenesis as well as tumor-stromal remodeling (120, 121). Additionally, CCL4 can also increase tumor infiltration of a variety of immune cell types including T lymphocytes, by signaling through CCR5 (122). Whether MIF-dependent CCL4 expression in TANS has pro- or anti-tumorigenic effects likely depends on which immune cells infiltrate and how the tumor microenvironment specifically activates these cells.

In another study (please see Table 1 for a summary of noted studies used for this review and corresponding references) investigating a non-melanoma skin cancer (NMSC) mouse model induced by chronic UVB exposure (123), MIF-deficient mice exhibited reduced tumor growth that corresponded to significant reductions in dermal neutrophil infiltration and associated myeloperoxidase activity. This finding is particularly interesting as NMSC tumor initiation is largely due to enduring inflammatory responses and highlights the fact that MIF’s effect as a pro-inflammatory cytokine can also promote tumor growth in the context of chronic inflammation. Further studies employing additional time points of MIF-dependent regulating TAN biology and effector functions will likely reveal additional examples by which MIF promotes TAN-dependent tumor initiation in early-stage tumors through chronic inflammation and, likely, as tumors progress and develop, this phenotype may switch to tumor-associated MIF in driving TAN-associated immune evasion.

### NATURAL KILLER (NK) CELLS

NK cells are an innate immune subset of lymphocytes that exhibit potent anti-tumor cell activity both through their cytolytic function as well as by regulating adaptive immune responses. As such, NK cells are increasingly being utilized clinically for induction of anti-tumor immune responses (124, 125).

Cancer cells evade anti-tumor adaptive immune responses, in part, by downregulating MHC class I (MHC-I) molecules which are required for CD8+ cytotoxic T lymphocyte (CTL)-dependent activation and cytotoxicity. In MHC-Ilo tumors, anti-tumor CTL responses are lost and thus immune checkpoint inhibitor (ICI) immunotherapies are often ineffective. In contrast to CTLs, NK cells specifically recognize and lyse cells that do not express MHC-I. While substantial efforts have been made to restore MHC-I expression on tumors to allow for more effective CTL-mediated immunotherapy (126), harnessing the cytotoxic activity of NK cells in MHC-Ilo tumors represents a very attractive alternative to initiate or boost anti-tumor immunity (125).

One of the very first descriptions of an immune-suppressive function for MIF came from a study where an NK cell inhibitory activity was discovered in the aqueous humor (AH) of the eye which, when micro-sequenced, was identified to be MIF (127). Subsequent validation experiments found that neutralizing anti-MIF attenuated the NK inhibitory activity in the AH and purified recombinant mouse MIF recapitulated the AH NK inhibitory activity. Importantly, neither AH nor rMIF had any direct effect on CTL mediated lysis of allogeneic cells, and rMIF’s inhibition of NK activity corresponded to inhibition of perforin granule release by NK—but not CTL—cells.

Subsequent studies by the same group speculated that uveal melanoma—the most common intraocular cancer in adults (128)—may similarly utilize secreted MIF to evade NK-mediated cytolysis at the site of primary outgrowth and at sites of metastatic dissemination. Local and metastatic uveal melanoma cell lines were found to secrete copious amounts of MIF with metastatic lines averaging more than 2x the MIF secretion as primary cells and this melanoma-derived MIF was protective in two of the cell line supernatants tested.

Subsequent studies found that MIF-dependent NK cell inhibitory functions are not restricted to the aqueous humor and uveal melanoma cells of the eye. MIF overexpression in ovarian cancer cell lines also promotes immune evasion in NK
cells; in this case by inducing the transcriptional downregulation of ovarian tumor target cell NKG2D that triggers NK-mediated tumor cell cytolysis (129).

An alternative mechanism for MIF-dependent inhibition of NK cell-mediated cytolysis was proposed following the fortuitous discovery that native—but not denatured —MIF is specifically recognized by a rat MHC class I monoclonal antibody and polyclonal anti-MIF antibodies bind to MHC class I (130). Recombinant MIF blocks MHC class I tetramer binding to NK cells suggesting that MIF may block NK function by competing for NK MHC class I molecules. The implication of this finding is that MIF contains an MHC class I structural motif that is capable of competing for HLA proteins thereby minimizing de novo NK cytolytic activities. Interestingly and perhaps relatedly, the cognate MIF receptor, CD74, is also known as the MHC class II invariant chain (24), which transports MHC class II molecules from the ER to the Golgi to allow for efficient late endosome peptide loading onto class II proteins (131–133). Finally, a recombinant HLA-DR protein was recently developed that was associated CD74 which serves to actively disrupt MIF binding resulting, ultimately, in significantly reduced disease severity in models of experimental autoimmune encephalomyelitis (134).

**T LYMPHOCYTES**

T lymphocytes are essential effectors of anti-tumor immunity and are the primary targets of ICI immunotherapies (135). Multiple T lymphocyte subtypes are recruited to and infiltrate tumor stroma which, when combined, ultimately determines relative tumor immunity. These subtypes include CD8+ cytotoxic T lymphocytes (CTL) (136), CD4+ helper T cells (137), FOXP3+ regulatory T cells (Tregs) (138), Th17 lymphocytes (139), and γδ T cells (140).

The first description of a functional role for MIF in T cell activation reported that murine splenocytes co-cultured with neutralizing anti-MIF antibody and activated by antigen, PMA/Ionomycin, or anti-CD3 exhibited significantly reduced IL-2 expression and concurrent reductions in T cell proliferation (7). MIF expression was further shown to be induced primarily in Th2 T lymphocyte subsets and was necessary for maximal antigen-specific antibody generation in vivo.

A subsequent study looking at the re-activation and relative CTL activity of in vivo primed splenocytes found that anti-MIF specifically increased CTL activity against the same irradiated syngeneic tumor cell line in vitro while control mAb and rMIF had no effect (141). While this study suggested that CTL-derived MIF directly inhibited anti-tumor CTL activity of primed lymphocytes, a separate finding indicated that tumor-derived MIF is similarly inhibitory to T cell activation and acts by inducing activation-induced T cell death via an IFN-γ-dependent pathway (114).

**Regulatory T cells (Treg)**

CD4+CD25+FOXP3+ effector regulatory T cells (Treg) infiltrate into the tumor stroma as well as tumor-draining lymph nodes and potently suppress anti-tumor immunity (138, 142). Suppressive mechanisms include inhibiting IL-2 production (143), expressing/secretion immune-suppressive cytokines (e.g. IL-10, IL-35, TGF-β) (144–146), CTLA-4-dependent downregulation of co-stimulatory molecules (i.e. CD80 and CD86) on APCs (147) resulting in T cell anergy (148), ectonucleotidases that hydrolyze ATP to adenosine (149) and direct lysis of effector T cells through perforin-dependent cytotoxicity (150).

In mouse models of mammmary and colon carcinoma, MIF promotes the generation/expansion of CD4+CD25+FOXP3+ Tregs by increasing IL-2 expression in activated splenocytes (151). Loss of host-derived MIF resulted in a decrease in intrasplenic and intratumoral Treg following tumor inoculation and this corresponded with an increase in splenic CD4+ and CD8+ T cells and a decrease in tumor outgrowth. Interestingly, complete tumor rejection was observed in a subset of MIF−/− mice that coincided with significant decreases in Treg and corresponding increases in splenic CD4+ and CD8+ lymphocytes. No changes in the expression of functional Treg markers (i.e. CTLA-4, GITR, IFN-γ, TGF-β, and IL-10) from MIF-deficient mice suggesting that MIF regulates Treg via expansion/generation rather than modulation of Treg effector functions.

**Gamma Delta T Cells (γδ T)**

γδ T cells are a rare T cell subtype that express the γ and δ (versus α and β) chains of the T cell receptor (TCR). These cells—similar to CD4+ T cells—have effector functions that can either support or suppress anti-tumor immunity (140). γδ T cells that positively influence anti-tumor immunity express IFN-γ that serves to both activate antigen-experienced CD4+ and CD8+ αβ T cells (152) and increase the expression of MHC-I molecules on tumor cells (153). In this context, IFN-γγδ T cells that co-express NKG2D can directly lyse cancer cells through recognition and interaction with MICA and MICB on tumor cells (154, 155). In contrast, γδ T cells that suppress anti-tumor immunity are characterized by reduced IFN-γ expression and high expression of interleukin 17 (IL-17) (156). γδ T17 cell-elicited IL-17 promotes tumorigenesis by increasing tumor infiltration of TAMs and MDSCs (157, 158), inducing autocrine immune-suppressive PD-L1 expression and on neighboring tumor cells (159) and directly promoting endothelial cell activation resulting in increased angiogenesis (160). In pancreatic ductal adenocarcinoma γδ T17 cells express high levels of PD-L1 resulting in the active suppression of anti-tumor αβ T cells resulting in increased tumor progression (161).

Although there are no reports of MIF driving γδ T cell effector functions in the context of tumorigenesis, MIF has been shown to regulate γδ T cell expression of IL-17 following stimulation with IL-1β and IL-23 in a mouse model of Gram-positive toxic shock syndrome (162). Interestingly, addition of recombinant MIF to lymph node-derived cells directly increases IL-17 production further supporting an amplification role for MIF in the regulation of γδ T17 cell-expressed IL-17 (163). Given that MIF can influence either pro- or anti-inflammatory phenotypes in other cell types depending on the type and severity of disease, further studies into whether, and if so how, MIF controls variable γδ T cell functions (i.e. via specific induction of either IFN-γ, IL-17 and/or PD-L1) in models of tumor progression are needed.
**T Helper 17 (Th17) Cells**

As their name implies, Th17 cells are a subset of IL-17-producing CD4+ helper T cells that arise when naïve CD4+ cells are exposed to specific cytokine signals such as TGF-β, IL-1β, and/or IL-6 and are further maintained by IL-21 and IL-23 (139). Similar to γδ T cells, Th17 lymphocytes have a variety of functions in the context of tumorogenesis (164). Pro-inflammatory Th17 responses drive colitis-induced cancer initiation/progression via chronic inflammation (165) while soluble IL-17-derived from Th17 cells increases tumor-associated de novo angiogenesis and tumor growth (166). Th17 responses have also been linked to the recruitment and immunosuppressive activity of CD11b+Gr-1+ MDSCs (167), and suppression of CD4+ and CD8+ T effector functions via ectonucleotidase expression (168). In contrast, Th17-derived IL-17 is also shown to promote anti-tumor immunity by enhancing IFN-γ NK- and effector T cell activation (169) and CCL20-dependent tumor and draining lymph node infiltration of DCs resulting in increased antigen-specific activation of CTLs (170). At least some of these apparent discrepancies may be due to the differential expression of IL-17 isoforms, IL-17A vs. IL-17F, the site of malignancy, and other Th17-elicited cytokines (164, 171).

The first description of MIF-dependent regulation of Th17 responses came from studies showing that rMIF addition to a heterogeneous population of nodal lymphocytes results in a dramatic increase of IL-17 expression (163). Subsequent studies found that tumor-derived MIF increases the expansion and migration of anti-tumor Th17 cells in nasopharyngeal carcinoma through CXCR4 which ultimately was associated with a more favorable clinical outcome (172). Conversely, clinical analysis of circulating cytokines in women with breast cancer found that MIF expression is increased in later stage and more aggressive molecular cancer subtypes and strongly correlates with IL-17 (173). MIF has also been implicated in non-tumor associated IL-17 expression in a variety of autoimmune disorders including Hashimoto’s thyroiditis (174) and rheumatoid arthritis (RA) (175) where Th17 responses are well-characterized to drive pro-inflammation.

MIF has two functional promoter polymorphisms that increase the transcription of MIF and both are associated with susceptibility to rheumatoid arthritis (176, 177). Not coincidentally, the addition of rMIF to RA patient-derived PBMCs increases IL-17 expression to levels similar to that observed with PBMCs from an individual with a high expression MIF polymorphism haplotype (175). Finally, using a murine model of psoriasiform dermatitis induced by IL-23—a critical determinant of Th17 lymphocyte responses (178)—MIF-deficiency resulted in a dramatic reduction of disease progression (179).

**B LYMPHOCYTES**

Although not traditionally thought of as central determinants in driving tumor immunity, several recent studies implicate specific B cell subtypes and tertiary lymphoid structures (TLS) in facilitating anti-tumor immune responses and immune checkpoint blockade (ICB) efficacy in various cancer types (180–182).

In the early 1980s, Ishizaka and colleagues described a soluble polypeptide secreted by antigen-stimulated splenocytes that inhibited the de novo glycosylation of T cell-associated IgE-binding factor (later identified as the low-affinity IgE Fc receptor, CD23). This soluble protein was called glycosylation-inhibiting factor (GIF) for obvious reasons but the net effect of this GIF activity on decreasing CD24 glycosylation was a selective suppression of IgE synthesis on B lymphocytes (183, 184). Not coincidentally, upon purifying and micro-sequencing the isolated GIF polypeptide, it was found to be identical to the MIF amino acid sequence and when the cDNA was cloned, it was identical to the translated MIF cDNA apart from one amino acid residue in the c-terminus that was later found to be due to a technical error in the original cDNA sequencing of MIF. Interestingly, recombinant MIF has no GIF activity which led to the discovery that GIF/MIF suppressive activities on IgE antibody responses requires a post-translational modification (185) later identified as a cysteinylation of Cys-60 in GIF/MIF-proteins (186).

The bulk of studies investigating MIF in B cell biology have stemmed from those evaluating the functional significance of the MIF/CD74 interaction in B cell lymphoma. Initial studies by the Shachar group showed that MIF-dependent CD74 activation drives IL-8 expression that acts to sustain chronic lymphocytic leukemia (CLL) cell survival (187). Subsequent studies found that Tap63, VLA4, and Bcl-2 are additional MIF/CD74 effectors responsible for driving CLL cell survival and homing to the bone marrow (188, 189). Less clear from these findings in B cell lymphoma is whether MIF/CD74 interactions are important in de novo B cell antibody responses and/or anti-tumor immunity.

Interestingly, CD74 and MIF’s non-cognate receptor (and CD74 co-receptor) CXCR4 are differentially expressed in transitional (CD19+CD27−CD38hiCD24hi) and naïve mature (CD19+CD27hiCD38lo) vs. activated class-switched memory (CD19+CD27IgG+) B cells, which suggests that MIF may be important for the differentiation and/or activation of these B cell subsets (190). Although these findings were in the context of autoimmune (190), the more recent findings that patients that respond to ICB treatment have a higher intratumoral frequency of un-switched and switched memory (CD19+CD27IgD−/−) B cells (181) suggests that further and more detailed investigation of whether/how MIF affects B cell class switching during tumorogenesis is warranted.

All things combined, MIF influences B cell activation pathways at multiple stages of development and maturation but whether these activation phenotypes occur during tumorogenesis and extrapolate to tumor immunity is largely unexplored. Since MIF influences B cell proliferation, class switching, and cytokine production—concurrent with the seminal discoveries of the roles of B cells and TLS in ICB therapeutic efficacy—a better understanding of MIF’s role in B cell biology specifically as it relates to tumor immunity will likely
reveal additional and important functional roles for MIF in governing tumor immune responses.

**DISCUSSION**

MIF is unusual among traditional cytokines. It lacks a traditional amino acid leader secretory sequence (191), it has reasonably high steady-state expression in most naive, un-activated immune effector cells (5, 7), and it contains a very well-conserved enzymatic active site (192). MIF’s functions in eliciting either pro- or anti-tumor immune responses in individual effector cell types are numerous and often context-dependent. Generally speaking, during early tumor initiation and outgrowth, MIF supports pro-inflammatory immune phenotypes governed by early infiltrating or resident macrophages and inflammatory IL-17 producing T lymphocytes that, collectively, increase inflammation and, likely, cell and tissue damage. As tumors progress into bulkier, more immune-suppressive advanced-stage disease, MIF phenotypes begin to more closely resemble that of wound resolution activities and, in this context, MIF—both tumor cell-derived and immune effector cell-derived—switches to initiating pro-tumorigenic immune evasion and neovascular processes in a variety of immune cell types (Figure 2).

**FIGURE 2** | Known and putative effects of MIF on tumor-infiltrating immune cells. Graphical depiction of immune effector cells known to be influenced by MIF. Sources of intratumoral MIF include both paracrine acting tumor-secreted and autocrine acting immune cell-secreted MIF. Phenotypes ascribed to tumor-derived MIF on individual cell types are listed next to each corresponding arrow to each cell type, while autocrine-associated activities are noted next to each cell with the caveat that those activities validated using recombinant MIF sources are noted with an asterisk.

![Diagram showing effects of MIF on tumor-infiltrating immune cells](image-url)
It is still not entirely clear how these individual MIF functions are governed and why they are frequently dependent on both the disease state and course/severity of the pathology. Multiple lines of evidence indicate that MIF’s site of action—via either cell surface receptor engagement or direct intracellular protein-protein interaction, is responsible for eliciting specific effector functions observed in individual immune cell types. One possible scenario involves a model where differential expression of CD74 and/or its various MIF co-receptors change as a result of tumor stage, immune effector cell infiltration, metabolic imbalance, and/or relative oxygenation; all of which would be expected to alter the relative phenotypic effects of soluble tumor-derived or immune effector cell-derived MIF in outside-in signaling. Less clear is whether and/or how intracellular MIF activities are differentially regulated and whether the MIF involved in these processes is from an intracellular cytosolic pool or an extracellular pool that is translocated into the cytosol (18).

An important consideration not discussed in this review is the respective role and contributions of the MIF ortholog, MIF-2, in tumor immunity. MIF-2 cooperatively signals with MIF in outside-in signaling by shared interactions with CD74 (36, 193–195), so it is plausible that where MIF-2 is co-expressed with MIF in either immune cell effectors or in tumor cells, the net effect is enhanced phenotypic tumor immunity as discussed with each of the cell types above. There is a lot to be learned about MIF-2’s differential expression in various immune effector cell types—whether MIF-2 shares similar binding activities with other MIF co-receptors and what, if any, intracellular binding proteins are shared with MIF.

Clearly MIF (and likely MIF-2) represents an intriguing and potentially clinically efficacious immunotherapeutic target for the management of malignant diseases. Several clinical trials have been undertaken and/or are currently underway investigating prospective MIF or MIF receptor inhibition in human cancers. A phase I study (NCT01765790) assessed the safety, pharmacokinetics, tolerability, and antitumor activity of a humanized anti-MIF monoclonal antibody (Imalumab) against solid cancers consisting primarily of colorectal carcinoma (50%), ovarian carcinoma (20%), and non-small cell lung carcinoma (NSCLC—14%) (196). Despite some toxicity issues with grade 3 allergic alveolitis, stable disease was observed in 26% of patients treated. Intriguingly, the tumor types that responded best to Imalumab were immune responsive tumors like NSCLC, ovarian, and esophageal—perhaps supporting the possibility that neutralizing MIF therapies may provide immunotherapeutic protections (196). Unfortunately, follow-up phase I/IIa and phase IIa studies were prematurely terminated for logistical reasons (poor study design and enrollment) and overall benefit-risk assessment, respectively.

An antibody targeting CD74 (Milatuzumab) underwent clinical trials (NCT00504972) and has been granted Orphan Drug Designation by the FDA for the treatment of CLL and multiple myeloma (197, 198). A CXCR4 inhibitor was previously approved to mobilize hematopoietic cells for transplantation in patients with multiple myeloma and non-Hodgkin’s lymphoma (199). Interestingly, a Phase II study (NCT02826486) is currently investigating the utility of another CXCR4 antagonist in combination with Pembrolizumab (anti-PD-1) immunotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (200).

As MIF small molecule inhibitor targeting is further refined and optimized (98, 99, 201), additional studies will explore both monotherapeutic and combination immune therapeutic targeting of MIF. Given that MIF functionally regulates the infiltration, expansion, and immune-suppressive phenotypes of such a variety of immune cell subtypes that collectively govern tumor immunity, further translational studies will be exceptionally informative.

**AUTHOR CONTRIBUTIONS**

JN reviewed literature, composed the figures and helped to write the manuscript. RM reviewed literature and wrote and organized the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported in part by NIH NCI R01CA186661 (RM), NIH (CoBRE) GB130096P3 (RM), and NIH NCI F30CA222550 (JN).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.609948/full#supplementary-material

**REFERENCES**

1. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev* (2018) 32:1267–84. doi: 10.1101/gad.314617.118

2. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. *Science* (1966) 153:80–2. doi: 10.1126/ science.153.3731.80

3. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. *Proc Natl Acad Sci USA* (1966) 56:72–7. doi: 10.1073/pnas.56.1.72

4. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. *Proc Natl Acad Sci USA* (1989) 86:7522–6. doi: 10.1073/pnas.86.19.7522

5. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. *J Exp Med* (1994) 179:1895–902. doi: 10.1084/jem.179.6.1895

6. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. *Nat Rev Immunol* (2003) 3:791–800. doi: 10.1038/nri1200

7. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-
cell activation. Proc Natl Acad Sci USA (1996) 93:7849–54. doi: 10.1073/pnas.93.15.7849
8. Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal (2019) 57:76–88. doi: 10.1016/j.cellsig.2019.01.006
9. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 14:e218–228. doi: 10.1016/S1470-2045(12)70582-X
10. Koh HM, Kim DC. Prognostic significance of macrophage migration inhibitory factor expression in cancer patients: A systematic review and meta-analysis. Med (Baltimore) (2020) 99:e21575. doi: 10.1097/MD0000000000021575
11. Xiao W, Dong X, Zhao H, Han S, Nie R, Zhang X, et al. Expression of MIF and c-erbB-2 in endometrial cancer. Mol Med Rep (2016) 13:3828–34. doi: 10.3892/mmr.2016.4992
12. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of macrophage migration inhibitory factor Mr expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res (2002) 8:3755–60.
13. Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY, Zhang N, et al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer (2011) 129:2463–72. doi: 10.1002/ijc.25918
14. Olsson L, Lindmark G, Hammarstrom ML, Hammarstrom S, Sitohy B. Interleukin-10 regulating macrophage migration inhibitory factor expression as a prognostic biomarker in colon cancer. Tumour Biol (2020) 42:1014082320942542. doi: 10.1177/1014082320942542
15. Flieger O, Engling A, Bucala R, Lue H, Nickel W, Bernhagen J. Regulated secretion of macrophage migration inhibitory factor is mediated by a non-classical pathway involving an ABC transporter. FEBS Lett (2003) 551:78–86. doi: 10.1016/S0014-5793(03)00900-1
16. Kleemann R, Grell M, Mischke R, Zimmermann G, Bernhagen J. Receptor binding and cellular uptake studies of macrophage migration inhibitory factor (MIF): use of biologically active labeled MIF derivatives. J Interferon Cytokine Res (2002) 22:351–63. doi: 10.1089/107999002753675785
17. Xie L, Qiao W, Xu Y, Tang J. beta-Arrestin1 mediates the endocytosis and functions of macrophage migration inhibitory factor. PloS One (2011) 6: e16428. doi: 10.1371/journal.pone.0016428
18. Kleemann R, Haussler A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jabb1. Nature (2000) 408:211–6. doi: 10.1038/35041591
19. Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, et al. The AP-1 Transcription Factor c-Jun Promotes Arthritis by Regulating Cyclooxygenase-2 and Arginase-1 Expression in Macrophages. J Immunol (2017) 198:3605–14. doi: 10.4049/jimmunol.1601330
20. Carr TM, Wheaton JD, Houtz GM, Ciofani M. JunB promotes Th17 cell identity and restrains alternative CD4(+) T-cell programs during inflammation. Nat Commun (2017) 8:301. doi: 10.1038/s41467-017-00380-3
21. Lue H, Dewor M, Leng L, Bucala R, Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal (2011) 23:135–44. doi: 10.1016/j.cellsig.2010.08.013
22. Coleman AM, Rendøn BE, Zhao M, Qian MW, Bucala R, Xin D, et al. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol (2008) 181:2330–7. doi: 10.4049/jimmunol.181.4.2330
23. Xin D, Rendøn BE, Zhao M, Winner M, McGhee Coleman A, Mitchell RA. The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through beta-catenin-dependent and -independent mechanisms. Mol Cancer Res (2010) 8:1601–9. doi: 10.1158/1541-7786.MCR-10-0111
24. Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J (2007) 26:987–97. doi: 10.1038/sj.emboj.7601564
25. Winner M, Koong AC, Rendøn BE, Zundel W, Mitchell RA. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res (2007) 67:186–93. doi: 10.1158/0008-5472.CAN-06-3292
26. Winner M, Leng L, Zundel W, Mitchell RA. Macrophage migration inhibitory factor manipulation and evaluation in tumoral hypoxic adaptation. Methods Enzymol (2007) 435:355–69. doi: 10.1016/S0076-6879(07)51018-0
27. Baugh JA, Gantier M, Li L, Byrne A, Buckley A, Donnelly SC. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochim Biophys Acta (2006) 1743:7489–93. doi: 10.1016/j.bbcan.2006.06.148
28. Benis L, Chan DA, Finkelstein CV, Qi L, Sutphin PD, Chen X, et al. Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev (2004) 18:739–44. doi: 10.1101/gad.1180104
29. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity (2014) 41:518–28. doi: 10.1016/j.immuni.2014.09.008
30. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA (2012) 109:2491–6. doi: 10.1073/pnas.1113744109
121. Quintero-Fabian S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Araguez V, Lara-Riegos J, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol (2019) 9:1370. doi: 10.3389/fonc.2019.01370

122. Vilgelm AE, Richmond A. Chemokines Modulate Immune Surveillance in Tumor Immunity. Front Immunol (2019) 10:333. doi: 10.3389/fimmu.2019.00333

123. Martin J, Duncan FJ, Keiser T, Shin S, Kusewitt DF, Oberyszyn T, et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC). FASEB J (2009) 23:720–30. doi: 10.1096/fj.08-119628

124. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2016) 16:7–19. doi: 10.1038/nrc.2015.5

125. Vacca P, Pietra G, Tumino N, Munari E, Mingari MC, Moretta L. Exploiting Human NK Cells in Tumor Therapy. Front Immunol (2019) 10:3013. doi: 10.3389/fimmu.2019.03013

126. Garrido F, Aptsiauri N, Doorduin EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol (2016) 39:44–51. doi: 10.1016/j.cell.2015.12.007

127. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol (1998) 160:5693–6.

128. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol (2000) 165:710–5. doi: 10.4049/jimmunol.165.2.710

129. Kroczenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hauser S, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 180:7338–48. doi: 10.4049/jimmunol.180.11.7338

130. Gibbons DJ, Ghetu AF, Dery R, Befs AD. Macrophage migration inhibitory factor has a MHC class I-like motif and function. J Exp Med (1997) 180:1599–60.

131. Castellino F, Zhong G, Germain RN. Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse dominant capture. Hum Immunol (1997) 54:159–69. doi: 10.1016/S0198-8859(97)00078-5

132. Germain RN. Uncovering the role of invariant chain in controlling MHC class II antigen capture. J Immunol (2011) 187:1073–5. doi: 10.4049/jimmunol.1101663

133. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med (1994) 180:1107–13. doi: 10.1084/jem.180.3.1107

134. Meza-Romoero B, Benedek G, Yu X, Mooreyen JL, Dahan R, Divashiani N, et al. HLA-D(Ral)pha1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. J Immunol (2014) 192:4164–73. doi: 10.4049/jimmunol.1303118

135. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol (2020) 20 (11):651–68. doi: 10.1038/s41577-020-0306-5

136. Hemanishi J, Mandai M, Iwasaki M, Okazaki T, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med (1998) 188:287–96. doi: 10.1084/jem.188.2.287

137. Steinbrink K, Wollf M, Jonuleit H, Knap J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 159:4722–80.

138. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450:566–9. doi: 10.1038/nature06306

139. Jarnicki AG, Lysaght I, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 177:896–904. doi: 10.4049/jimmunol.177.5.896

140. Perez VL, Van Parijs L, Buickians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6:411–7. doi: 10.4049/jimmunol.177.2.896

141. Choi S, Kim HR, Leng L, Kang I, Jorgensen WL, Cho CS, et al. Role of macrophage migration inhibitory factor in inhibitory T cell function on tumor-bearing mice. J Immunol (2012) 189:3905–13. doi: 10.4049/jimmunol.1102152

142. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 198:433–42. doi: 10.1084/jem.20030584

143. Fleming C, Morrissey S, Cai Y, Jan J. Gamma delta T cells: Unexpected Regulators of Cancer Development and Progression. Trends Cancer (2017) 3:3561–70. doi: 10.1016/j.trecan.2017.06.003

144. Steinbrink K, Wollf M, Jonuleit H, Knap J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 159:4722–80.

145. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450:566–9. doi: 10.1038/nature06306

146. Jarnicki AG, Lysaght I, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 177:896–904. doi: 10.4049/jimmunol.177.5.896

147. Wing K, Onushi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 322:271–5. doi: 10.1126/science.1160062

148. Perez VL, Van Parijs L, Buickians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6:411–7. doi: 10.4049/jimmunol.177.2.896

149. Choi S, Kim HR, Leng L, Kang I, Jorgensen WL, Cho CS, et al. Role of macrophage migration inhibitory factor in inhibitory T cell function on tumor-bearing mice. J Immunol (2012) 189:3905–13. doi: 10.4049/jimmunol.1102152

150. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 198:433–42. doi: 10.1084/jem.20030584

151. Fleming C, Morrissey S, Cai Y, Jan J. Gamma delta T cells: Unexpected Regulators of Cancer Development and Progression. Trends Cancer (2017) 3:3561–70. doi: 10.1016/j.trecan.2017.06.003

152. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, et al. IL-17A produced by gamma delta T cells promotes tumor growth by promoting angiogenesis. Eur J Immunol (2010) 40:1927–37. doi: 10.1002/eji.20094157
161. Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, et al. gammadelta T Cells Support Pancreatic Oncogenesis by Restraining alphabeta T Cell Activation. Cell (2016) 166:1485–99. doi:10.1016/j.cell.2016.07.046
162. Kim HK, Garcia AB, Siu E, Tlstam P, Das R, Roberts S, et al. Macrophage migration inhibitory factor regulates innate gammadelta T-cell responses via IL-17 expression. FASEB J (2019) 33:6919–32. doi:10.1096/fj.20182433R
163. Stojanovic I, Cvejetinac T, Lazaros S, Stosic-Grusic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology (2009) 126:74–83. doi:10.1111/j.1365-2567.2008.02897.x
164. Zou W, Restifo NP, ThJ17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 10:248–56. doi:10.1038/nri2742
165. Keerthivasan S, Aghajani K, Dose M, Molinero L, Khan MW, Venkateswaran V, et al. Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med (2014) 6:225ra228. doi:10.1126/scitranslmed.3007607
166. Namasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumour growth. Blood (2003) 101:260–72. doi:10.1182/blood-2002-05-1461
167. Chang SH, Mirabolollahinejad SG, Katta H, Cumpian AM, Gong L, Caetano P, et al. IL-17 expression and production in lymph node cells. Immunology (2009) 126:74–83. doi:10.1111/j.1365-2567.2008.02897.x
168. Hernandez-Palma LA, Garcia-Arellano S, Bucala R, Llamas-Covarrubias E. Macrophage Migration Inhibitory Factor (MIF) Drives Murine Preeclampsia. Dermatol Immunol (Front Immunol) (2018) 9:2262. doi:10.3389/fimmu.2018.02262
169. Cabrita R, Lauss M, Sanna A, Donia M, Skarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature (2020) 577:559–65. doi:10.1038/s41586-019-1914-8
170. Helmingk BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature (2020) 577:549–55. doi:10.1038/s41586-019-1922-8
171. Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature (2020) 577:556–60. doi:10.1038/s41586-019-1906-0
172. Watarai H, Nozawa R, Tokunaga A, Yuyama N, Tomis M, Hinohara A, et al. Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. Proc Natl Acad Sci USA (2000) 97:13251–6. doi:10.1073/pnas.2304553975
173. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA (2007) 104:13408–13. doi:10.1073/pnas.0701553104
174. Binsky I, Lantner F, Grabovsky V, Harpaz N, Shvidel L, Berrebi A, et al. TaP63 regulates VLA-4 expression and chronic lymphocytic leukemia cell migration to the bone marrow in a CD74-dependent manner. J Immunol (2010) 184:7461–9. doi:10.4049/jimmunol.0904149
175. Shahar I, Haran M. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk Lymphoma (2011) 52:1446–54. doi:10.1080/10428191.2011.565437
176. Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, et al. The immunoregulatory mediator macrophage migration inhibition factor (MIF) catalyzes a tautomeration reaction. Mol Med (1996) 2:143–9. doi:10.1007/BF03422010
177. Bennahmoune I, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry (1994) 33:928–36. doi:10.1021/bi00098a001
178. Roeck SE, Rendon BE, Yaddanapudi K, Mitchell RA. Negative regulation of AMP-activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem (2012) 287:35484–95. doi:10.1074/jbc.M112.367532
179. Avalos-Navarro G, Munoz-Valle JF, Daneri-Navarro A, Quintero-Ramos A, Franco-Topete RA, Moran-Mendoza AJ, et al. Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with the cytokine profile. J Clin Exp Med (2019) 193:85–91. doi:10.1007/s10241-019-05595-6
180. Xue H, Yang Z, Zhang Y, Song S, Zhang J, Ma L, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune diabetes in Hashimoto’s thyroiditis. Mediators Inflammation (2015) 2015:621072. doi:10.1155/2015/621072
181. Hernandez-Palma LA, Garcia-Arellano S, Bucala R, Llamas-Covarrubias MA. De la Cruz-Musso U, Oregon-Romero E, et al. Functional MIF promoter haplotypes module Th17-related cytokine expression in peripheral blood mononuclear cells from control subjects and rheumatoid arthritis patients. Cytokine (2019) 115:89–96. doi:10.1016/j.cyto.2018.11.014
182. Gregersen PK, Bucala R. Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum (2003) 48:1711–6. doi:10.1002/art.10880
183. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum (2005) 52:3020–9. doi:10.1002/art.21285
184. Lubberts E. The IL-23-17 axis in inflammatory arthritis. Nat Rev Rheumatol (2015) 11:415–29. doi:10.1038/nrrheum.2015.53
185. Betzke S, Leng L, Busch H, Mouavi S, Rades D, Dahlke M, et al. Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasis Dermatit. Front Immunol (2018) 9:2262. doi:10.3389/fimmu.2018.02262
198. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol (2013) 163:478–86. doi: 10.1111/ bjh.12565

199. Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, et al. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol (2019) 94:1244–53. doi: 10.1002/ ajh.25627

200. Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med (2020) 26:878–85. doi: 10.1038/s41591-020-0880-x

201. Trivedi-Parmar V, Jorgensen WL. Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor. J Med Chem (2018) 61:8104–19. doi: 10.1021/acs.jmedchem.8b00589

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Noe and Mitchell. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.